Background
==========

In 2017, laryngeal squamous cell carcinoma (LSCC) accounts for 13150 newly diagnosed and 3710 cancer-related deaths annually in the United States [@B1]. In 2015, the number reported in China was 26400 and 14500 respectively [@B2]. Tumor-Node-Metastasis (TNM) staging system is the most commonly used methodology in evaluating LSCC prognosis. However, there were some inter-individual differences observed in the same TNM stage LSCC patients. One possible reason is the case that the current TNM staging system does not fully explain tumor heterogeneity.

Recent studies have shown that chronic inflammation increasing the risk in many malignancies, including LSCC [@B3]-[@B6]. Neutrophils, as an inflammatory cell, could promote tumor cell growth and invasion by generating cytokines and vascular endothelial growth factors (VEGF) [@B7]-[@B9]. Platelets could assist tumor cells escaped from antitumor immunity and secret VEGF and platelet-derived growth factors (PDGF) [@B7], [@B10], [@B11]. Lymphocytes could stop tumor progression, and reflect the function of patients\' immune system [@B12]. Thus, some inflammation markers, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and lymphocyte/monocyte ratio (LMR), have been established to play a prognostic role in LSCC [@B13]-[@B17]. In previous study, we described a novel inflammation-based marker, albumin/globulin ratio (AGR) has a prognostic significance in LSCC [@B18]. However, the comparison of these markers in LSCC patients have not been investigated.

Therefore, the aim of current study was to explore and compare the prognostic value of different inflammation-based markers in an independent LSCC patient cohort, including AGR, NLR, PLR and LMR.

Material and methods
====================

Patients
--------

Three hundred and sixty-five patients with firstly diagnosed LSCC were retrospectively enrolled from January 2008 to December 2013. All surgeries were performed by the same experienced surgeon (Ji-Chun Yu) at the First/Second Affiliated Hospital of Nanchang University, China. The exclusion criteria were as following: (1) received any anti-cancer therapy previously (including radiotherapy/induction chemotherapy), n=56; (2) a history of previous/synchronous malignant tumors, n=12; (3) insufficient laboratory data before initial treatment, n=39; (4) known active inflammatory disorders (including autoimmune disease and infection) or active liver or kidney disease, n=26. In total, two hundred and thirty-two patients with LSCC were eligible for this study. Written informed consent for the collection of medical data of all patients was obtained. And the ethics committee approved the current study.

All patients were assessed by completed physical examination, fiber laryngoscopy, head and neck MRI (magnetic resonance imaging), abdominal ultrasonography, chest radiography, electrocardiography, and laboratory examination.

Data collection
---------------

Laboratory data collection was performed as the previous studies [@B18]. Specifically, all laboratory data (blood chemistry analysis) were acquired from patients within 7 days of any surgery. The AGR was calculated using the equation AGR= Albumin/ (total serum protein-albumin); the NLR was calculated using the equation NLR= neutrophils/lymphocytes; the PLR was calculated using the equation PLR= platelets/lymphocytes; the LMR was calculated using the equation LMR= lymphocytes/monocytes.

Treatment
---------

The standard treatment of this study was partial or total laryngectomy (+/- neck dissection) and postoperative radio-/chemotherapy according to the National Comprehensive Cancer Network guidelines. Postoperative radiotherapy or chemoradiotherapy was performed in patients with adverse features (including positive margins, pT4 primary, N2 or 3 nodal metastases, extracapsular node/perineural invasion).

Follow-up
---------

All patients were follow-up for every 3 months in the first 2 years, and every 6 months thereafter for up to 5 years or until death. Follow-up examination including fiber laryngoscopy, neck ultrasonography, MRI. The recurrence was defined as any newly found mass on imaging examination with histologically confirmed by biopsy or surgery. The end follow-up was December 2017.

Statistical analyses
--------------------

All analyses were performed using SPSS v22.0 (IBM Corporation, Armonk, New York, USA). Differences among groups were compared by the Chi-square test, Mann-Whitney *U* test for the different types of variables. Receiver operating characteristic (ROC) curves were plotted to determine the optimal cut-off value for AGR/NLR/PLR/LMR, and the area under the curve (AUC) were compared. The univariate and multivariate analysis were evaluated by the log-rank test and the cox proportional hazard model. A *P*\<0.05 was defined as statically significance.

Results
=======

Clinicopathological Features and Treatment Outcomes
---------------------------------------------------

232 LSCC patients\' clinicopathological features as showed in Table [1](#T1){ref-type="table"}. Of these patients, 192 (82.76%) were males, 40 (17.24%) were females. Their median age at diagnose was 63 (range, 39-81). According to the 7^th^ edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) staging system for LSCC, 113 patients (48.7%) were diagnosed stage III or IV. During a 27.3±18.6 months\' follow-up, 115 patients (49.6%) and 78 patients (33.6%) were experienced tumor recurrence and death, respectively. The median (range) for AGR, NLR, PLR, LMR was 1.30 (0.75-2.58), 2.98 (0.78-20.50), 109.00 (24.00-505.00), and 2.56 (0.77-18.87), respectively. And the optimal cut-off value, determined by the ROC analysis for overall survival (OS), for AGR, NLR, PLR, LMR was 1.31 (AUC: 0.707, 95% CI: 0.639-0.775, *P*\<0.001), 2.38 (AUC: 0.567, 95% CI: 0.509-0.641, *P*=0.044), 116.00 (AUC:0.607. 95% CI: 0.535-0.680, *P*=0.005), and 2.01 (AUC: 0.618, 95% CI: 0.546-0.690, *P*=0.002), respectively. And the AUC values were statistically compared to evaluate the discrimination ability of every inflammation-based marker (Figure [1](#F1){ref-type="fig"}). The AGR had significantly higher AUC value than NLR (*P*=0.011), PLR (*P*=0.039) and LMR (*P*=0.022).

Association of preoperative inflammation-based markers with clinical characteristics
------------------------------------------------------------------------------------

This cohort was divided into 2 groups using the optimal cut-off value for AGR, NLR, PLR and LMR, respectively (Table [2](#T2){ref-type="table"}). In the AGR subgroups, age, gender, smoking history, drinking history and differentiation grade were found no significant difference among two groups. However, tumor site (*P*=0.018), larger tumor size (*P*\<0.001), T~3+4~ stage (*P*\<0.001), lymph node metastasis (*P*\<0.001), and later TNM stage (III+IV, *P*\<0.001) were found to be associated with the lower AGR group. In the NLR subgroups, tumor size (*P*=0.022), T~3+4~ stage (*P*\<0.001), lymph node metastasis (*P*=0.021), later TNM stage (*P*=0.017) were associated with the higher NLR group. In the PLR subgroups, larger tumor size (*P*=0.016), T~3+4~ stage (*P*=0.011), later TNM stage (*P*=0.019) were associated with higher AGR group significantly. Besides, the lower LMR group was associated with larger tumor size (*P*=0.007), T~3+4~ stage (*P*\<0.001), lymph node metastasis (*P*\<0.001), later TNM stage (*P*=0.011).

Prognostic significance of clinicopathological features in LSCC patients
------------------------------------------------------------------------

In univariate analysis (Table [3](#T3){ref-type="table"}), gender, smoking history, drinking history, tumor size showed no significant association with a shorter OS or disease-free survival (DFS). However, tumor site, T~3+4~ stage, lymph node metastasis, later TNM stage, differentiation grade, AGR, NLR, PLR, and LMR were found to be associated with a shorter OS or DFS. Besides, age ≥60 was associated with OS, not DFS. Multivariate analyses were performed based on those markers with significance in the univariate analysis. We found that lymph node metastasis, later TNM stage, differentiation grade, AGR, NLR, PLR, LMR were independent prognostic markers for OS (Table [4](#T4){ref-type="table"}). And, lymph node metastasis, later TNM stage, AGR were still independent prognostic markers for DFS.

Prognostic significance of inflammation-based markers in LSCC patients
----------------------------------------------------------------------

In univariate analysis (Table [3](#T3){ref-type="table"}), the shorter OS was significantly associated with AGR (HR: 3.227, 95% CI: 1.692-4.395, *P*\<0.001), NLR (HR: 1.994, 95% CI: 1.126-3.374, *P*=0.031), PLR (HR: 1.815, 95% CI: 1.160-2.841, *P*=0.011), and LMR (HR: 2.291, 95% CI: 1.344-3.439, *P*=0.019). And the shorter DFS was significantly associated with AGR (HR: 3.512, 95% CI: 2.330-5.294, *P*\<0.001), NLR (HR: 2.295, 95% CI: 1.312-4.015, *P*\<0.001), PLR (HR: 1.826, 95% CI: 1.264-2.638, *P*=0.024), LMR (HR: 2.283, 95% CI: 1.433-3.635, *P*=0.012).

In multivariate analysis (Table [4](#T4){ref-type="table"}), AGR (HR: 3.479, 95% CI: 2.157-5.612, *P*\<0.001), NLR (HR: 1.295, 95% CI: 1.012-3.015, *P*=0.044), PLR (HR: 1.621, 95% CI: 1.083-2.427, *P*=0.021), LMR (HR: 1.898, 95% CI: 1.191-2.540, *P*=0.017) were independent prognostic markers of the shorter OS. However, NLR, PLR, and LMR showed no significance with the shorter DFS. AGR (HR: 2.595, 95% CI: 1.477-4.557, *P*\<0.001) remained an independent prognostic marker for the shorter DFS.

Kaplan-Meier survival analysis were performed and survival curves were plotted (Figure [2](#F2){ref-type="fig"}). Patients with lower AGR had a worse prognosis in 5-year OS (44.55% vs. 75.07%, *P*\<0.001) and DFS (26.50% vs. 71.04%,*P*\<0.001). The 5-year OS/DFS in patients with higher NLR was worse than lower NLR patients (OS: 77.45% vs. 55.92%, *P*=0.03; DFS: 69.92% vs. 42.73%,*P*=0.001). Patients with higher PLR had a lower 5-year OS (67.69% vs. 47.69%, *P*=0.001) and DFS (58.38% vs. 35.34%, *P*=0.001). And 5-year OS (53.62% vs. 74.15%, *P*=0.01) and DFS (39.62% vs. 67.93%,*P*\<0.001) in patients with lower LMR were worse than patients with higher LMR.

Discussion
==========

AGR, along with other inflammation-based markers, in the current study were associated with aggressive clinicopathological features and poor prognosis in LSCC patients. And AGR had a significantly higher AUC value compared with other inflammation-based markers in terms of predicting the prognosis of LSCC patients. To the best of our knowledge, this is the first study to specifically focus on the comparison of the prognostic value of AGR with other inflammation-based markers in cancer patients.

Over the last decade, various inflammation-based markers have been reported their prognostic role in many cancers [@B19]-[@B23], including LSCC [@B13]-[@B18]. In our previous report, we firstly described AGR as a prognostic marker for patients with LSCC. However, none of these studies have compared their prognostic value. In the current study, we found that all inflammation-based markers (NLR, PLR, LMR, AGR) associated with aggressive clinicopathological features (such as tumor size, lymph node metastasis, and late TNM stage) and have a significantly prognostic value for patients with LSCC, which was consistent with other reports.

It is widely recognized that cancer-associated inflammation plays a significant role in tumor progression [@B5], [@B24], though the exact mechanism is still unclear. At an early stage of cancer progression, various cytokines generated by cancer cells could recruit inflammatory cells that creating microenvironment, facilitating tumor growth, geomantic instabilities, and angiogenesis [@B25]-[@B27]. Neutrophils could promote cancer cells metastasis by secreting circulating growth factors [@B28]. Furthermore, neutrophils could weaken T lymphocytes\' function and promote cancer progression [@B29]-[@B31]. Lymphocytes induced cell death and inhibiting tumor cell migration and proliferation. Studies demonstrated that better prognosis was associated with a higher proportion of lymphocytes infiltration into the tumor stroma [@B32], [@B33]. In addition, platelets have been reported to directly interact with tumor cells by activating TGF-β/Smad and NF-κB pathways, inducing cancer cells epithelial-mesenchymal transition and thus promote cancer metastasis [@B34]. Furthermore, monocytes have been reported to promote tumor metastasis by circulation and the tumor-monocytes-endothelial interaction [@B35], [@B36]. Therefore, NLR, PLR, LMR play an important role in the prognosis of LSCC.

AGR not only reflects the systemic inflammatory responses, but dystrophia. Firstly, albumin has been widely used to evaluate the nutritional status and to predict the prognosis of cancer patients. Albumin has been reported various anticancer capabilities, including steadying cell growth and managing DNA replication, buffering many biochemical alterations, and its antioxidant effects which may against carcinogens [@B37]. Secondly, malnutrition and inflammation could prevent the synthesis of albumin. For instance, interleukin-6 promotes the generation of acute-phase reaction proteins in the liver and regulation of the synthesis of albumin by liver cells, whereas tumor necrosis factor can down-regulate the albumin gene transcription and increase the permeability of the microvasculature which leading to increased transcapillary passage of albumin [@B38]. Thirdly, high levels of globulins caused by aggregation of the acute-phase proteins and immunoglobulins, which reflect an inflammatory state in the tumor microenvironment [@B38].

In addition, we compared the prognosis value of the NLR, PLR, LMR and AGR by *Z* test in ROC analysis. This methodology has been validated in previous studies [@B39]. The results have shown that the AUC value of AGR is significantly more than the NLR, PLR, and LMR, which indicated that AGR may have a better discriminatory ability than other inflammatory markers in terms of prognosis for patients with LSCC. Since authors believe that not only systemic inflammation but nutritional status plays a role in cancer progression [@B40]-[@B42]. The AGR is the combination of these two predictors of adverse outcomes. Thus, it may explain AGR have a better predictive value in LSCC patients.

There are several limitations to the current study. The retrospective nature of this study may lead to an inevitable bias; therefore, an independent cohort with long-term follow-up is needed to further analyze the predictive value of these factors in LSCC patients. Additionally, the AGR were assessed at the preoperative single time point. The changes in blood over time and in response to treatment, and their relationships to the prognosis of LSCC patients may be the subject in the future study.

Conclusion
==========

Our findings show that the AGR may serve as a promising prognostic factor in LSCC patients, and have a better discriminatory ability than other inflammation-based markers. Further studies are warranted to validate the predictive role of AGR in a larger, prospective, multi-centers cohort.
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###### 

Baseline characteristics of enrolled patients

  Patient characteristics                                   n/mean±SD    
  --------------------------------------- ----------------- ------------ ------------
  Number of patients                                        232          
  Age at diagnosis (yrs, median, range)                     63 (39-81)   
  Sex (male/female)                                         192/40       
  Smokers (%)                                               133(57.7%)   
  Drinkers (%)                                              91(39.2%)    
  Tumor size (cm)                                           1.98±0.94    
  Tumor site (%)                                                         
                                          Glottic                        152(65.2%)
                                          Supraglottic                   68(29.3%)
                                          Subglottic                     12(5.2%)
  Differentiation grade                                                  
                                          Poor                           39(16.8%)
                                          Moderate & Well                193(83.2%)
  T stage III or IV (%)                                     106(45.7%)   
  Lymph node metastasis (N+) (%)                            112(48.3%)   
  TNM stage III or IV (%)                                   113(48.7%)   
  Recurrence (%)                                            115(49.6%)   
  Death (%)                                                 78(33.6%)    
  Follow-up months (m)                                      27.3±18.6    

###### 

Correlation between inflammation-based markers and clinicopathological characteristics of LSCC patients

  Characteristics         AGR                          NLR            PLR                         LMR                                                                                 
  ----------------------- -------------- ------------- ----------- -- ------------- ------------- ----------- -- ------------- ------------ --------- -- ------------- -------------- -----------
  Age (years)             \<1.31 n=119   ≥1.31 n=113   *P*            \<2.38 n=48   ≥2.38 n=184   *P*            \<116 n=130   ≥116 n=102   *P*          \<2.01 n=70   ≥ 2.01 n=162   *P*
  \<60                    54(45.4%)      59(52.2%)     0.301          24(50.0%)     89(48.4%)     0.832          59(43.4%)     54(52.9%)    0.247        36(51.4%)     77(47.5%)      0.589
  ≥60                     65(54.6%)      54(47.8%)                    24(50.0%)     95(51.6%)                    71(54.6%)     48(47.1%)                 34(48.6%)     85(52.5%)      
  Gender                                                                                                                                                                              
  Male                    98(82.4%)      94(83.2%)     0.859          40(83.3%)     152(82.6%)    0.908          107(82.3%)    85(83.3%)    0.836        59(84.3%)     133(82.1%)     0.681
  Female                  21(17.6%)      19(16.8%)                    8(16.7%)      32(17.4%)                    23(17.7%)     17(16.7%)                 11(15.7%)     29(17.9%)      
  Smoking history                                                                                                                                                                     
  No                      44(37.0%)      55(48.7%)     0.156          25(52.1%)     74(40.2%)     0.134          58(44.6%)     41(40.2%)    0.488        33(47.1%)     66(40.7%)      0.821
  Yes                     75(63.0%)      58(51.3%)                    23(47.9%)     110(59.8%)                   72(55.4%)     61(59.8%)                 37(52.9%)     96(59.3%)      
  Drinking history                                                                                                                                                                    
  No                      70(58.8%)      71(63.4%)     0.481          31(64.6%)     110(59.8%)    0.542          83(63.8%)     58(56.9%)    0.278        36(51.4%)     105(64.8%)     0.064
  Yes                     49(41.2%)      41(36.6%)                    17(35.4%)     74(40.2%)                    47(36.2%)     44(43.1%)                 34(48.6%)     57(35.2%)      
  Tumor site                                                                                                                                                                          
  Supraglottic            46(38.7%)      28(24.8%)     0.018\*        11(22.9%)     57(31.0%)     0.268          37(28.5%)     31(30.4%)    0.751        20(28.6%)     48(29.6%)      0.874
  Glottic&Subglottic      73(61.3%)      85(75.2%)                    37(77.1%)     127(69.0%)                   93(71.5%)     71(69.6%)                 50(71.4%)     114(70.4%)     
  Tumor size                                           \<0.001\*                                                                                                                      
  ≤2cm                    51(42.9%)      69(61.1%)                    32(66.7%)     88(47.8%)     0.022\*        76(58.5%)     44(43.1%)    0.016\*      28(40.0%)     92(56.8%)      0.007\*
  \>2cm                   68(57.1%)      44(38.9%)                    16(33.3%)     96(52.2%)                    54(41.5%)     58(56.9%)                 42(60.0%)     70(43.2%)      
  T Stage                                                                                                                                                                             
  T1+2                    58(48.7%)      83(73.5%)     \<0.001\*      37(77.1%)     104(56.5%)    \<0.001\*      88(67.7%)     53(52.0%)    0.011\*      33(47.1%)     108(66.7%)     \<0.001\*
  T3+4                    61(51.3%)      30(26.5%)                    11(22.9%)     80(43.5%)                    42(32.3%)     49(48.0%)                 37(52.9%)     54(33.3%)      
  Lymph node metastasis                  \<0.001\*                                                                                                                                    
  N0                      46(38.7%)      74(65.5%)                    32(66.7%)     88(47.8%)     0.021\*        70(53.8%)     50(49.0%)    0.471        15(21.4%)     105(64.8%)     \<0.001\*
  N+                      73(61.3%)      39(34.5%)                    16(33.3%)     96(52.2%)                    60(46.2%)     52(51.0%)                 55(78.6%)     57(35.2%)      
  TNM stage                                            \<0.001\*                                  0.017\*                                   0.019\*                                   0.011\*
  I+II                    42(35.3%)      77(68.1%)                    32(66.7%)     87(47.3%)                    75(57.7%)     44(43.1%)                 27(38.6%)     92(56.8%)      
  III-IV                  77(64.7%)      36(31.9%)                    16(33.3%)     97(52.7%)                    55(42.3%)     58(56.9%)                 43(61.4%)     70(43.2%)      
  Differentiation grade                  0.483                                      0.402                                      0.168                                   0.387          
  Poor                    18(15.1%)      21(18.6%)                    10(20.8%)     29(15.8%)                    18(13.8%)     21(20.6%)                 14(20.0%)     25(15.4%)      
  Moderate & Well         101(84.9%)     92(81.4%)                    38(79.2%)     155(84.2%)                   112(86.2%)    81(79.4%)                 56(80.0%)     137(84.6%)     

*Abbreviations: HR* hazard ratio, *95% CI* 95% confidencel interval, *AGR* albumin/globulin ratio

*NLR* neutrophil/lymphocyte ratio,*PLR* platelet/lymphocyte ratio,*LMR* lymphocyte/monocyte ratio*, LSCC* laryngeal squamous cell carcinoma

\* *P* \< 0.05 considered as statistically significant.

###### 

Univariate Cox proportional hazards regression analysis for overall survival (OS) and disease-free survival(DFS) in patients with laryngeal squamous cell carcinoma(LSCC)

                          OS                   P   DFS                  P      
  ----------------------- -------------------- --- -------------------- --- -- -----------
  Age(y)                                           0.022\*                     0.432
  \<60                    1                        1                           
  ≥60                     1.397(1.111-1.823)       1.197(0.611-1.323)          
  Gender                                           0.093                       0.214
  Male                    2.011(0.912-3.447)       1.921(0.745-2.422)          
  Female                  1                        1                           
  Smoking history                                  0.114                       0.192
  No                      1                        1                           
  Yes                     2.228(0.891-4.374)       1.765(0.889-3.018)          
  Drinking history                                 0.427                       0.514
  No                      1                        1                           
  Yes                     1.772(0.733-2.936)       1.234(0.533-2.109)          
  Tumor site                                       \<0.001\*                   \<0.001\*
  Supraglottic            2.101(1.506-2.930)       2.331(1.764-3.081)          
  Glottic&Subglottic      1                        1                           
  Tumor size                                       0.068                       0.114
  \<2cm                   1                        1                           
  ≥2cm                    1.781(0.996-2.578)       1.334(0.891-2.119)          
  T Stage                                          0.032\*                     0.019\*
  T1+2                    1                        1                           
  T3+4                    1.407(1.028-2.542)       1.604(1.112-2.315)          
  Lymph node metastasis                            0.024\*                     0.033\*
  N0                      1                        1                           
  N+                      2.012(1.342-2.997)       1.387(1.118-2.009)          
  TNM stage                                        \<0.001\*                   \<0.001\*
  I+II                    1                        1                           
  III-IV                  2.932(1.412-4.976)       1.668(1.152-2.416)          
  Differentiation grade                            0.012\*                     0.013\*
  Poor                    1.667(1.289-2.178)       1.433(1.198-2.090)          
  Moderate & Well         1                        1                           
  AGR                                              \<0.001\*                   \<0.001\*
  \<1.31                  3.227(1.692-4.395)       3.512(2.330-5.294)          
  ≥1.31                   1                        1                           
  NLR                                              0.031\*                     \<0.001\*
  \<2.38                  1                        1                           
  ≥2.38                   1.994(1.126-3.374)       2.295(1.312-4.015)          
  PLR                                              0.011\*                     0.024\*
  \<116                   1                        1                           
  ≥116                    1.815(1.160-2.841)       1.826(1.264-2.638)          
  LMR                                              0.019\*                     0.012\*
  \<2.01                  2.291(1.344-3.439)       2.283(1.433-3.635)          
  ≥2.01                   1                        1                           

Abbreviations: *HR* hazard ratio, *95% CI* 95% confidencel interval,*AGR* albumin/globulin ratio

*NLR* neutrophil/lymphocyte ratio,*PLR* platelet/lymphocyte ratio,*LMR* lymphocyte/monocyte ratio

\* *P* \< 0.05 considered as statistically significant.

###### 

Multivariate Cox proportional hazards regression analysis for overall survival (OS) and disease-free survival (DFS) in patients with laryngeal squamous cell carcinoma (LSCC)

                          OS                   *P*   DFS                  *P*                  
  ----------------------- -------------------- ----- -------------------- ----- -- ----------- --
  Age(y)                                             0.757                         \-          
  \<60                    1                          \-                                        
  ≥60                     1.127(0.781-1.423)                                                   
  Tumor site                                         0.379                         0.543       
  Supraglottic            1.262(0.634-2.513)         2.026(0.564-2.328)                        
  Glottic&Subglottic      1                          1                                         
  T Stage                                            0.393                         0.229       
  T1+2                    1                          1                                         
  T3+4                    1.007(0.450-2.004)         1.219(0.512-1.925)                        
  Lymph node metastasis                              0.021\*                       0.048\*     
  N0                      1                          1                                         
  N+                      1.512(1.332-2.294)         1.561(1.322-2.976)                        
  TNM stage                                          \<0.001\*                     \<0.001\*   
  I+II                    1                          1                                         
  III-IV                  2.014(1.397-2.904)         2.403(1.768-3.266)                        
  Differentiation grade                              0.041\*                       0.376       
  Poor                    1.327(1.008-2.178)         1.234(0.582-1.992)                        
  Moderate & Well         1                          1                                         
  AGR                                                \<0.001\*                     \<0.001\*   
  \<1.31                  3.479(2.157-5.612)         2.595(1.477-4.557)                        
  ≥1.31                   1                          1                                         
  NLR                                                0.044\*                       0.611       
  \<2.38                  1                          1                                         
  ≥2.38                   1.295(1.012-3.015)         1.243(0.536-2.883)                        
  PLR                                                0.021\*                       0.089       
  \<116                   1                          1                                         
  ≥116                    1.621(1.083-2.427)         1.546(0.946-2.527)                        
  LMR                                                0.017\*                       0.874       
  \<2.01                  1.898(1.191-2.540)         1.104(0.446-1.950)                        
  ≥2.01                   1                          1                                         

*Abbreviations: HR* hazard ratio, *95% CI* 95% confidence interval, *AGR* albumin/globulin ratio

*NLR* neutrophil/lymphocyte ratio,*PLR* platelet/lymphocyte ratio,*LMR* lymphocyte/monocyte ratio

\* *P* \< 0.05 considered as statistically significant.
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